Legal & General Group PLC Regeneron Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$423 Billion
Q1 2024

A detailed history of Legal & General Group PLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 977,941 shares of REGN stock, worth $1.02 Billion. This represents 0.22% of its overall portfolio holdings.

Number of Shares

977,941

Previous 977,941 -0.0%

Holding current value

$1.02 Billion

Previous $941 Million -0.0%

% of portfolio

0.22%

Previous 0.22%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$902.69 - $993.35 $6.86 Million - $7.55 Million	-7,599 Reduced 0.77%	977,941 $941 Million
Q4 2023 Feb 15, 2024	BUY	$775.18 - $881.7 $128 Million - $146 Million	165,332 Added 20.16%	985,540 $866 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $18.6 Million - $22.7 Million	-26,921 Reduced 3.18%	820,208 $675 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $1.4 Million - $1.66 Million	-1,998 Reduced 0.24%	847,129 $609 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $12.1 Million - $14.7 Million	17,758 Added 2.14%	849,127 $698 Million

Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $29.4 Million - $31.9 Million	-41,616 Reduced 4.77%	831,369 $600 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $5.91 Million - $7.46 Million	-10,302 Reduced 1.17%	872,985 $601 Million
Q2 2022 Aug 22, 2022	BUY	$548.35 - $738.84 $41.3 Million - $55.7 Million	75,391 Added 9.33%	883,287 $522 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $34.2 Million - $40.1 Million	57,387 Added 7.65%	807,896 $564 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $8.48 Million - $10.5 Million	-15,609 Reduced 2.04%	750,509 $474 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $12.1 Million - $14.3 Million	21,066 Added 2.83%	766,118 $464 Million
Q2 2021 Aug 12, 2021	BUY	$472.8 - $558.54 $17.2 Million - $20.3 Million	36,408 Added 5.14%	745,052 $416 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $6.51 Million - $7.99 Million	-14,582 Reduced 2.02%	708,644 $335 Million
Q4 2020 Feb 12, 2021	BUY	$478.3 - $607.98 $19.1 Million - $24.3 Million	39,979 Added 5.85%	723,226 $349 Million
Q3 2020 Nov 13, 2020	SELL	$544.75 - $658.21 $5 Million - $6.04 Million	-9,181 Reduced 1.33%	683,247 $382 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $77.9 Million - $102 Million	157,929 Added 29.55%	692,428 $432 Million
Q1 2020 May 14, 2020	BUY	$336.18 - $494.43 $4.1 Million - $6.03 Million	12,205 Added 2.34%	534,499 $261 Million
Q4 2019 Feb 13, 2020	BUY	$274.13 - $376.51 $5.79 Million - $7.95 Million	21,108 Added 4.21%	522,294 $196 Million
Q3 2019 Nov 13, 2019	BUY	$273.46 - $318.39 $2 Million - $2.33 Million	7,319 Added 1.48%	501,186 $139 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $4.62 Million - $6.39 Million	15,410 Added 3.22%	493,867 $155 Million
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $35 Million - $41.3 Million	93,957 Added 24.44%	478,457 $196 Million
Q4 2018 Feb 15, 2019	BUY	$335.82 - $403.04 $8.23 Million - $9.87 Million	24,498 Added 6.8%	384,500 $144 Million
Q3 2018 Nov 20, 2018	BUY	$351.14 - $408.51 $3.09 Million - $3.59 Million	8,792 Added 2.5%	360,002 $145 Million
Q2 2018 Aug 10, 2018	SELL	$284.6 - $344.99 $3.92 Million - $4.75 Million	-13,767 Reduced 3.77%	351,210 $121 Million
Q1 2018 May 17, 2018	BUY	$315.82 - $393.78 $1.09 Million - $1.35 Million	3,437 Added 0.95%	364,977 $126 Million
Q4 2017 Feb 13, 2018	BUY	$358.63 - $469.95 $130 Million - $170 Million	361,540	361,540 $136 Million

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Regeneron Pharmaceuticals, Inc. Transaction History